Simplified production of SARS-CoV-2-pseudotyped lentivirus

A common objective in developing COVID-19 therapies is to demonstrate inhibition of SARS-CoV-2 infection. Given the safety measures required in handling live SARS-CoV-2, researchers often employ alternative viruses pseudotyped with the SARS-CoV-2 spike protein. To support these efforts, we have adapted our Lenti-X packaging system to enable high-titer production of spike-pseudotyped lentiviral particles in a convenient format and developed an accompanying cell line stably expressing the human ACE2 receptor.

Lenti-X SARS-CoV-2 Packaging Single Shots (Universal) gives you the flexibility to choose any existing or emerging SARS-CoV-2 spike protein variant for lentiviral pseudotyping.   

In addition, packaging systems are available for the production of viral particles bearing your choice of the following SARS-CoV-2 spike protein variants:

• WT (full length)—derived from the Wuhan-Hu-1 isolate (NC_045512.2) of SARS-CoV-2 and codon-optimized for expression in mammalian cells
• D614G (full length)—includes the D614G mutation in the spike protein-coding sequence
• B.1.351 (full length)—derived from SARS-CoV-2 variant originally identified in South Africa (20H/501.V2)
• WT (truncated), D614G (truncated), and B.1.351 (truncated)—truncations of WT spike, D614G spike, and B.1.351 spike coding sequences involving removal of 19 amino acids from C-termini; the truncation is associated with increased abundance of spike protein on the resulting particles, and increased particle infectivity